Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Eradivir Closes $10.25M Series A Funding Round

2024-09-25
WEST LAFAYETTE, IN, Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round.
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors